AU2021370660A1 - Heterocyclic spiro compounds and methods of use - Google Patents
Heterocyclic spiro compounds and methods of use Download PDFInfo
- Publication number
- AU2021370660A1 AU2021370660A1 AU2021370660A AU2021370660A AU2021370660A1 AU 2021370660 A1 AU2021370660 A1 AU 2021370660A1 AU 2021370660 A AU2021370660 A AU 2021370660A AU 2021370660 A AU2021370660 A AU 2021370660A AU 2021370660 A1 AU2021370660 A1 AU 2021370660A1
- Authority
- AU
- Australia
- Prior art keywords
- amino
- methyl
- diazaspiro
- octan
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020123913 | 2020-10-27 | ||
| CNPCT/CN2020/123913 | 2020-10-27 | ||
| PCT/US2021/056702 WO2022093856A1 (en) | 2020-10-27 | 2021-10-26 | Heterocyclic spiro compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021370660A1 true AU2021370660A1 (en) | 2023-06-08 |
Family
ID=78650109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021370660A Pending AU2021370660A1 (en) | 2020-10-27 | 2021-10-26 | Heterocyclic spiro compounds and methods of use |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230406860A1 (https=) |
| EP (1) | EP4237086A1 (https=) |
| JP (1) | JP2023549055A (https=) |
| AU (1) | AU2021370660A1 (https=) |
| CA (1) | CA3199082A1 (https=) |
| MX (1) | MX2023004802A (https=) |
| WO (1) | WO2022093856A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| IL310291A (en) | 2021-07-23 | 2024-03-01 | Theras Inc | Compositions and methods for inhibition of ras |
| AR128211A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| AR128212A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| CN117186107A (zh) * | 2022-05-31 | 2023-12-08 | 成都先导药物开发股份有限公司 | 一种制备2-取代-5,7-二羰基-2,6-二氮杂螺[3,4]辛烷中间体的方法 |
| CN120659773A (zh) | 2022-11-09 | 2025-09-16 | 锐新医药公司 | 化合物、复合物以及其制备方法和用途 |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008017691A1 (en) | 2006-08-10 | 2008-02-14 | Glaxo Group Limited | Pyridine derivatives as sodium channel blockers |
| EP2683716A1 (en) * | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| ES2898765T3 (es) * | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| US11136308B2 (en) * | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| MX2021000887A (es) * | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
| EP3887373A1 (en) * | 2018-11-29 | 2021-10-06 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| JP2022513967A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| JP7686559B2 (ja) | 2018-12-20 | 2025-06-02 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| EP3908283A4 (en) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
-
2021
- 2021-10-26 WO PCT/US2021/056702 patent/WO2022093856A1/en not_active Ceased
- 2021-10-26 US US18/033,439 patent/US20230406860A1/en active Pending
- 2021-10-26 EP EP21810231.7A patent/EP4237086A1/en active Pending
- 2021-10-26 AU AU2021370660A patent/AU2021370660A1/en active Pending
- 2021-10-26 JP JP2023524901A patent/JP2023549055A/ja active Pending
- 2021-10-26 MX MX2023004802A patent/MX2023004802A/es unknown
- 2021-10-26 CA CA3199082A patent/CA3199082A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230406860A1 (en) | 2023-12-21 |
| MX2023004802A (es) | 2023-06-22 |
| JP2023549055A (ja) | 2023-11-22 |
| WO2022093856A1 (en) | 2022-05-05 |
| EP4237086A1 (en) | 2023-09-06 |
| CA3199082A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022093856A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP7654071B2 (ja) | 複素環スピロ化合物及び使用方法 | |
| EP4479401A1 (en) | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins | |
| JP2024532733A (ja) | 複素環式化合物及び使用方法 | |
| AU2022328206A1 (en) | Heterocyclic compounds and methods of use | |
| US20250059205A1 (en) | Heterocyclic Compounds and Methods of Use | |
| WO2022232332A1 (en) | 2-aminobenzothiazole compounds and methods of use thereof | |
| US20250179077A1 (en) | Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins | |
| AU2023356610A1 (en) | Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| JP2024532734A (ja) | 複素環式化合物及び使用方法 | |
| CN117561063A (zh) | 杂环化合物及使用方法 | |
| CN117897159A (zh) | 杂环化合物及使用方法 | |
| CN117835976A (zh) | 杂环化合物及使用方法 | |
| HK40070481A (en) | Fgfr inhibitors and methods of use thereof |